Novartis initiates Phase 3 trial of Pelabresib plus Ruxolitinib in Myelofibrosis
Novartis is conducting Phase 3 trial to assess the efficacy of Pelabresib combined with Ruxolitinib in patients with myelofibrosis who have not received prior JAK inhibitor therapy.